Hepatitis B virology for clinicians

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 397-408

  Doo, Edward C ^a   Ghany, Marc G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antiviral Therapy; CccDNA; Hepatitis B virus; Polymerase

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; VIRUS DNA;

CLINICAL FEATURE; DIAGNOSTIC TEST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; REVIEW; VIRION; VIROGENESIS; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS PARTICLE; DRUG EFFECTS; FORECASTING; GENETICS; PERSONALIZED MEDICINE; PHYSIOLOGY; RNA INTERFERENCE; TRENDS; VIROLOGY; VIRUS ENTRY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; FORECASTING; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INDIVIDUALIZED MEDICINE; RNA INTERFERENCE; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 77954649544     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.001     Document Type: Review

References (52)

1. Seeger C., Zoulim F., Mason W.S. Hepadnaviridae. Fields virology 2007, Lippincott-Raven Publishers, Philadelphia. 5th edition. D.M. Knipe, B. Roizman, P.M. Howley (Eds.).
2. Gerber M.A., Hadziyannis S., Vissoulis C., et al. Electron microscopy and immunoelectronmicroscopy of cytoplasmic hepatitis B antigen in hepatocytes. Am J Pathol 1974, 75:489-502.
3. Gavilanes F., Gonzalez-Ros J.M., Peterson D.L. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins. J Biol Chem 1982, 257:7770-7777.
4. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000, 64:51-68.
5. Milich D., Liang T.J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003, 38:1075-1086.
6. Perrillo R., Campbell C., Wellinghoff W., et al. The relationship of hepatitis B e antigen, DNA polymerase activity, and titer of hepatitis B surface antigen with ongoing liver injury in chronic hepatitis B virus infection. Am J Gastroenterol 1982, 77:445-449.
7. Hoofnagle J.H., Dusheiko G.M., Seeff L.B., et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981, 94:744-748.
8. Cross J.C., Wen P., Rutter W.J. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci U S A 1993, 90:8078-8082.
9. Bouchard M.J., Schneider R.J. The enigmatic X gene of hepatitis B virus. J Virol 2004, 78:12725-12734.
10. Glebe D., Urban S., Knoop E.V., et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005, 129:234-245.
11. Klingmuller U., Schaller H. Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol 1993, 67:7414-7422.
12. Kock J., Schlicht H.J. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993, 67:4867-4874.
13. Sohn J.A., Litwin S., Seeger C. Mechanism for CCC DNA synthesis in hepadnaviruses. PLoS One 2009, 4:e8093.
14. Pollack J.R., Ganem D. An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol 1993, 67:3254-3263.
15. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005, 42:302-308.
16. Tuttleman J.S., Pourcel C., Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986, 47:451-460.
17. Newbold J.E., Xin H., Tencza M., et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995, 69:3350-3357.
18. Wu T.T., Coates L., Aldrich C.E., et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990, 175:255-261.
19. Levrero M., Pollicino T., Petersen J., et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009, 51:581-592.
20. Mason W.S., Cullen J., Moraleda G., et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998, 245:18-32.
21. Yuen M.F., Wong D.K., Sum S.S., et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol 2005, 100:1099-1103.
22. Wong D.K., Yuen M.F., Ngai V.W., et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006, 11:909-916.
23. Bourne E.J., Dienstag J.L., Lopez V.A., et al. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat 2007, 14:55-63.
24. Werle-Lapostolle B., Bowden S., Locarnini S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-1758.
25. Moraleda G., Saputelli J., Aldrich C.E., et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997, 71:9392-9399.
26. Fourel I., Cullen J.M., Saputelli J., et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994, 68:8321-8330.
27. Guo J.T., Zhou H., Liu C., et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000, 74:1495-1505.
28. Thimme R., Wieland S., Steiger C., et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003, 77:68-76.
29. Guidotti L.G., Rochford R., Chung J., et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
30. Wursthorn K., Lutgehetmann M., Dandri M., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-684.
31. Sung J.J., Wong M.L., Bowden S., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-1897.
32. Belloni L., Pollicino T., De Nicola F., et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A 2009, 106:19975-19979.
33. Turin F., Borel C., Benchaib M., et al. n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J Virol 1996, 70:2691-2696.
34. Ghany M., Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007, 132:1574-1585.
35. Bartholomeusz A., Tehan B.G., Chalmers D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004, 9:149-160.
36. Bartenschlager R., Junker-Niepmann M., Schaller H. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol 1990, 64:5324-5332.
37. Bartenschlager R., Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 1992, 11:3413-3420.
38. Weber M., Bronsema V., Bartos H., et al. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J Virol 1994, 68:2994-2999.
39. Zoulim F., Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994, 68:6-13.
40. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677.
41. Das K., Xiong X., Yang H., et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001, 75:4771-4779.
42. Deres K., Schroder C.H., Paessens A., et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299:893-896.
43. Bourne C.R., Finn M.G., Zlotnick A. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol 2006, 80:11055-11061.
44. Stray S.J., Bourne C.R., Punna S., et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A 2005, 102:8138-8143.
45. Stray S.J., Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit 2006, 19:542-548.
46. King R.W., Ladner S.K., Miller T.J., et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1998, 42:3179-3186.
47. Delaney W.E., Edwards R., Colledge D., et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 2002, 46:3057-3060.
48. Feld J.J., Colledge D., Sozzi V., et al. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007, 76:168-177.
49. Block T.M., Lu X., Mehta A.S., et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998, 4:610-614.
50. Mehta A., Carrouee S., Conyers B., et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 2001, 33:1488-1495.
51. Petersen J., Dandri M., Mier W., et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008, 26:335-341.
52. Wilson R., Purcell D., Netter H.J., et al. Does RNA interference provide new hope for control of chronic hepatitis B infection?. Antivir Ther 2009, 14:879-889.